Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

1711 - Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial

Date

10 Oct 2016

Session

Gastrointestinal tumours, colorectal 2

Presenters

Julien Taieb

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

J. Taieb1, K. Le Malicot2, R. Balogoum3, J. Tabernero4, E. Mini5, G. Folprecht6, J. van Laethem7, J. Emile8, C. Mulot9, S. Fratté10, C. Levaché11, L. Saban-Roche12, J. Thaler13, L. Nørgård Petersen14, E. Sanchez15, J. Bridgewater16, G. Perkins3, C. Lepage17, A. Zaanan18, P. Laurent-Puig3

Author affiliations

  • 1 Department Of Gastroenterology And Gi Oncology; Université Paris Descartes, Hopital European George Pompidou, 75000 - Paris/FR
  • 2 Biostatistics, Fédération Francophone de Cancérologie Digestive (FFCD), 21079 - Dijon/FR
  • 3 Université Paris Descartes, Sorbonne Paris Cité, France; Department Of Biology, Hôpital Européen Georges Pompidou, Paris, France; Inserm Umr-s1147, Assistance Publique - Hopitaux De Paris, Paris/FR
  • 4 Oncologia Médica, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 5 Section Of Internal Medicine, University of Florence, Dpt of experimental and clinical medicine, Florence/IT
  • 6 Department Of Internal Medicine I, University Hospital Carl Gustav, 1307 - Dresden/DE
  • 7 Dept. Of Gastroenterology, Erasme University Hospital-(Universite Libre de Bruxelles), 1070 - Brussels/BE
  • 8 Pathology Department, Hopital Ambroise Pare, Boulogne-Billancourt/FR
  • 9 Depatment Of Biology, Hopital Européen Georges Pompidou, Inserm Umr-s1147, Assistance Publique - Hopitaux De Paris, Paris/FR
  • 10 Department Of Gastroenterology, Centre Hospitalier de Belfort-Monbéliard, Montbéliard/FR
  • 11 Department Of Radiotherapy And Medical Oncology, Polyclinique Francheville, Périgueux/FR
  • 12 Department Of Medical Oncology, Institut de Cancérologie de la Loire, Saint-Priest-En-Jarez/FR
  • 13 Dept. Internal Medicine Iv, Klinikum Wels - Grieskirchen, 4600 - Wels/AT
  • 14 Department Of Oncology, Rigshospitalet, Kobenhavn/DK
  • 15 Gruppo Cooperativo Do Cancro Digestivo Da Associação Portuguesa De Investigação Oncológica (gccd, Apio), - Instituto Português de Oncologia do Porto Francisco Gentil, Porto/PT
  • 16 University College London, UCL - University College London, WC1E 6DD - London/GB
  • 17 Hepato-gastroenterology Department, Dijon University Hospital And Inserm U866, Fédération Francophone de Cancérologie Digestive (FFCD), 21079 - Dijon/FR
  • 18 Department Of Gastroenterology And Gi Oncology; Université Paris Descartes, Hopital European George Pompidou, Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1711

Background

RAS mutations have been shown to confer resistance to anti-EGFR treatment. We assessed here the results of the PETACC8 trial (Cetuximab + FOLFOX vs FOLFOX) in full wild type (WT) patients (pts) (RAS & BRAF). The prognostic impact of individual rare RAS and BRAF mutations has been tested.

Methods

Exons 2, 3 and 4 of KRAS and NRAS as well as BRAF exon 11 and 15 have been sequenced, using the ampliseq colon lung cancer panel V2, among the pts who have signed informed consent for translational research. The impact of cetuximab on Time To Recurrence (TTR), Disease Free Survival (DFS) and Overall Survival (OS), has been investigated in pts RAS WT, RAS & BRAF double WT tumors and in pts with rare RAS mutations.

Results

Among the 2559 pts analyzed, 745 (29%) were known to be mutated for KRAS exon 2 and 163 (6.4%) for BRAF V600E. From the remaining 1654 pts 1054 had given informed consent for additional TR analyses and were NGS assessed, with 227 pts (21%) newly diagnosed as KRAS exon 3,4 or NRAS exon 2,3,4 mutated, and 46 (4.4%) as non-V600E BRAF mutated. Cetuximab was not improving significantly TTR, DFS or OS in pts with RAS WT or RAS & BRAF double WT tumors (HR ranging from 0.77 to 1.05, all p > 0.05). FOLFOX + Cetuximab was either not significantly deleterious in RAS mutant pts (HR ranging from 1.13 to 1.29, all p > 0.05). Outcome was not significantly different with and without cetuximab in pts with RAS or BRAF rare mutations (HR ranging from 1.42 to 1.61, all p > 0.05). When pooling both treatment arms, as compared to double WT pts, KRAS and NRAS codon 61 rare mutants were associated with a worse TTR (KRAS, HR : 2.42 [1.40;4.20] p = 0.001 and NRAS, HR : 2.18 [1.21;3.93] p = 0.008) and DFS (KRAS, HR: 1.98 [1.15;3.42] p = 0.01 and NRAS, HR: 1.99 [1.13;3.50] p = 0.015). This was not the case for other RAS or BRAF rare mutations.

Conclusions

In Stage III colon cancer, the addition of cetuximab to standard FOLFOX adjuvant therapy does not improve significantly outcome in RAS and RAS & BRAF double WT pts. No detrimental significant effect was observed in RAS mutant pts. NRAS or KRAS codon 61 seem to be the only rare mutations that has the same pejorative prognostic value than KRAS codon 12 and 13 or BRAF V600E mutations.

Clinical trial identification

EudraCT number 2005-003463-23

Legal entity responsible for the study

N/A

Funding

Merck and Sanofi

Disclosure

J. Taieb: Honoraria from: Merck Amgen Lilly Sanofi Celgene Roche Glycart. J. Tabernero: Advisory role for Consultant/Advisory role: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Takeda and Taiho. G. Folprecht: Advisory role for: Roche Merck KGaA Lilly ImClome Bristol-Myers Squibb He received honoraria from: Merck KGaA He received research funding from Merck KgaA. J-F. Emile: Honoraria from: Merck Serono Roche Glycart He had avisory role for: Merck Serono Roche Glycart. C-B. Levaché: Honoraria from: Amgen Roche Glycart He had advisory role for: Amgen Roche Glycart He was speaker's bureau and expert testimony for: Amgen. J. Thaler: Honoraria and research funding from: Sanofi Merck. L. Nørgård Petersen: Advisory role for Bayer and Roche Glycart. J. Bridgewater: Advisory role for Merck Serono. He received money for travel, accommodatioons, expenses from MSD Oncology and Merck Serono. He received honoraria from Merck Serono. G. Perkins: Advisory role for Sanofi. She received money for travel, accommodations from Sanofi, Celgene, and Roche Glycart. C. Lepage: Money for travel, accommodations and expenses from Ipsen. A. Zaanan: Advisory role for Merck, Amgen, Sanofi, Lilly, and Roche Glycart. P. Laurent-Puig: Advisory role for Sanofi, Merck Serono, Amgen, Genomic Health, Myriad Genetics, Integragen, Prizer, Roche Glycart. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings